File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2217/hep-2016-0010
- PMID: 30191050
- WOS: WOS:000406848900004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: When to consider liver transplantation in hepatocellular carcinoma patients?
Title | When to consider liver transplantation in hepatocellular carcinoma patients? |
---|---|
Authors | |
Keywords | Bridging therapy Down-staging therapy Extended criteria Hepatocellular carcinoma Immunosuppressant Liver transplantation Milan Criteria Salvage transplantation |
Issue Date | 2017 |
Publisher | Future Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/hep |
Citation | Hepatic Oncology, 2017, v. 4 n. 1, p. 15-24 How to Cite? |
Abstract | Orthotopic liver transplantation (LT) has been regarded as the best cure among the three curative treatment modalities. However, when to consider LT in hepatocellular carcinoma (HCC) patients remains a complicated clinical question. In this article, we will look into the recent updates in the context of LT for HCC, including the timing of orthotopic LT (primary or salvage LT), patient selection criteria, newer prognostic markers and scoring systems, down-staging and bridging therapy, salvage LT and treatment option of post-LT HCC recurrence. Evolution of immunosuppressive therapy and future development of the LT for HCC will also be discussed. |
Persistent Identifier | http://hdl.handle.net/10722/245319 |
ISSN | 2023 Impact Factor: 1.2 2023 SCImago Journal Rankings: 0.155 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ma, KW | - |
dc.contributor.author | Cheung, TT | - |
dc.date.accessioned | 2017-09-18T02:08:31Z | - |
dc.date.available | 2017-09-18T02:08:31Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Hepatic Oncology, 2017, v. 4 n. 1, p. 15-24 | - |
dc.identifier.issn | 2045-0923 | - |
dc.identifier.uri | http://hdl.handle.net/10722/245319 | - |
dc.description.abstract | Orthotopic liver transplantation (LT) has been regarded as the best cure among the three curative treatment modalities. However, when to consider LT in hepatocellular carcinoma (HCC) patients remains a complicated clinical question. In this article, we will look into the recent updates in the context of LT for HCC, including the timing of orthotopic LT (primary or salvage LT), patient selection criteria, newer prognostic markers and scoring systems, down-staging and bridging therapy, salvage LT and treatment option of post-LT HCC recurrence. Evolution of immunosuppressive therapy and future development of the LT for HCC will also be discussed. | - |
dc.language | eng | - |
dc.publisher | Future Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/hep | - |
dc.relation.ispartof | Hepatic Oncology | - |
dc.subject | Bridging therapy | - |
dc.subject | Down-staging therapy | - |
dc.subject | Extended criteria | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Immunosuppressant | - |
dc.subject | Liver transplantation | - |
dc.subject | Milan Criteria | - |
dc.subject | Salvage transplantation | - |
dc.title | When to consider liver transplantation in hepatocellular carcinoma patients? | - |
dc.type | Article | - |
dc.identifier.email | Cheung, TT: cheung68@hku.hk | - |
dc.identifier.authority | Cheung, TT=rp02129 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.2217/hep-2016-0010 | - |
dc.identifier.pmid | 30191050 | - |
dc.identifier.pmcid | PMC6095144 | - |
dc.identifier.hkuros | 278105 | - |
dc.identifier.volume | 4 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 15 | - |
dc.identifier.epage | 24 | - |
dc.identifier.isi | WOS:000406848900004 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 2045-0923 | - |